Holen Sie sich die Stockscreener-App
1.76
2.33%
0.04
Handel nachbörslich:
1.76
Bluejay Diagnostics Inc Aktie (BJDX) Neueste Nachrichten
Bluejay Diagnostics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Bluejay fixes sepsis test production issues, keeps 510(k) plan in view - Stock Titan
Bluejay Diagnostics (NASDAQ: BJDX) Q1 loss highlights urgent $20M funding need - Stock Titan
Bluejay Diagnostics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Bluejay Diagnostics Provides First Quarter 2026 Corporate Update - The Manila Times
Bluejay Diagnostics (NASDAQ: BJDX) details Q1 2026 cash and sepsis test progress - Stock Titan
BJDX Stock Price, Quote & Chart | BLUEJAY DIAGNOSTICS INC (NASDAQ:BJDX) - ChartMill
Bluejay Diagnostics (NASDAQ: BJDX) seeks reverse split and major stock plan expansion - Stock Titan
BJDX Technical Analysis | Trend, Signals & Chart Patterns | BLUEJAY DIAGNOSTICS INC (NASDAQ:BJDX) - ChartMill
Bluejay Diag (BJDX) Innovation Pipeline | Q4 2023: Profit DisappointsMargin Compression - newser.com
BJDX Ownership | BLUEJAY DIAGNOSTICS INC (NASDAQ:BJDX) - ChartMill
Why Is Bluejay Diagnostics, Inc. (BJDX) Stock Down Today? - Meyka
Board seeks flexible reverse split, plan increase at Bluejay Diagnostics (NASDAQ: BJDX) - Stock Titan
Is Bluejay Diag (BJDX) stock risky (Slight Dip) 2026-04-20Social Flow Trades - Cổng thông tin điện tử Tỉnh Sơn La
bjdx stock: Bluejay Diagnostics Overview - Bitget
Aug Summary: How is Bluejay Diagnostics Inc managing supply chain issues2026 Technical Patterns & Growth Focused Entry Reports - baoquankhu1.vn
Macro Review: Is Bluejay Diagnostics Inc gaining market share2026 Trading Recap & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Bluejay Diagnostics Nears Completion of SYMON-II Clinical Trial with 624 Patient Enrollments for Symphony IL-6 Sepsis Test - Minichart
Bluejay Nears Completion of Pivotal SYMON-II Sepsis Trial - TipRanks
SYMON-II sepsis trial nears full enrollment at Bluejay (NASDAQ: BJDX) - Stock Titan
Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial - Bitget
Bluejay Diagnostics, Inc. Announces Completion Of 624 Patient Enrollments In Symon-Ii Pivotal Clinical Trial - TradingView — Track All Markets
Bluejay Diagnostics Achieves Milestone with 624 Patients Enrolled in Pivotal SYMON-II Trial for IL-6 Testing in Sepsis Management - Quiver Quantitative
BJDX Technical Analysis & Stock Price Forecast - Intellectia AI
Are insiders buying or selling Bluejay Diag (BJDX) Stock | Price at $1.95, Up 3.17%Pro Trader Recommendations - UBND thành phố Hải Phòng
Volume Recap: Why is Bluejay Diagnostics Inc stock going down2026 Pullback Review & Weekly Top Performers Watchlists - baoquankhu1.vn
Analyst Upgrade: How is Bluejay Diagnostics Inc managing supply chain issuesNew Guidance & Real-Time Buy Zone Alerts - baoquankhu1.vn
BJDX SEC FilingsBluejay Diagnostics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
BJDX PE Ratio & Valuation, Is BJDX Overvalued - Intellectia AI
Bluejay Diagnostics, Inc. Enters Securities Purchase Agreement for $25,000 Private Placement of Common Stock - Minichart
Bluejay Diagnostics Announces Insider-Funded Private Stock Placement - TipRanks
Bluejay Diagnostics completes $125,000 private placement with board members - Investing.com
Bluejay Diagnostics Raises $125,000 in Insider Private Placement at $2.00 Per Share - tradingview.com
Bluejay Diagnostics (NASDAQ: BJDX) insiders purchase $125K in private stock deal - stocktitan.net
Fed Meeting: Is Bluejay Diagnostics Inc gaining market shareEntry Point & Weekly Return Optimization Alerts - baoquankhu1.vn
Bluejay Diagnostics, Inc. announced that it has received $0.125 million in funding - marketscreener.com
Bluejay Diagnostics Evaluates Potential Acquisition Opportunity While Prioritizing Core Critical Care Platform Initiatives - Minichart
Bluejay Diagnostics sends response letter to NorthStrive Fund II LP By Investing.com - Investing.com India
Bluejay Diagnostics sends response letter to NorthStrive Fund II LP - Investing.com
Bluejay Weighs Proposed Therapeutic Acquisition, Reaffirms Symphony Focus - TipRanks
Bluejay responds to investor on possible therapeutic acquisition while prioritizing Symphony platform execution - TradingView
Bluejay Diagnostics (BJDX) reviews NorthStrive proposal for cough therapy acquisition - Stock Titan
Buyout Rumor: What is Bluejay Diagnostics Incs book value per shareTrade Exit Summary & Real-Time Volume Analysis - baoquankhu1.vn
Bluejay Diagnostics, Inc. announced that it expects to receive $0.125 million in funding - marketscreener.com
Bluejay Advances Symphony IL-6 Sepsis Diagnostic Program - TipRanks
Bluejay Diagnostics: SYMON-I IL-6 Findings Accepted for SAEM 2026 Presentation - TradingView
Bluejay Diagnostics (NASDAQ: BJDX) highlights SYMON-I IL-6 sepsis data at 2026 SAEM - Stock Titan
Bluejay Diagnostics to Present Findings on IL-6 as a Biomarker for Sepsis at 2026 SAEM Annual Meeting - Quiver Quantitative
Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting - The Manila Times
Study explores link between ER inflammation marker and organ damage in sepsis - Stock Titan
Northstrive Fund II has sent a letter to the Board of Directors of Bluejay Diagnostics Inc, recommending that they carefully evaluate a potential acquisition opportunity. - Bitget
NorthStrive Fund II LP Issues Open Letter to the Board and Shareholders of Bluejay Diagnostics - The Manila Times
Braeden Lichti Pushes for Changes at Bluejay Diagnostics with 3.65% Stake - TradingView
3.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):